Gloucester pharmaceuticals
Celgene to Buy Gloucester Pharmaceuticals – DealBook Blog …
Celgene, the biopharmaceutical company, said on Monday that it has agreed to buy Gloucester Pharmaceuticals for as much as $640 million to bolster its anticancer drug pipeline.
Celgene buying Gloucester Pharma for $640 million – KansasCity.com
Biotechnology company Celgene Corp. said Monday it will buy privately held Gloucester Pharmaceuticals Inc. for $640 million, getting access to key cancer drugs.
Gloucester Pharmaceuticals to Present Positive Results from …
Poster presentations on studies in cutaneous T-cell, Nov 24, 2009 – Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclini.
Gloucester Pharmaceuticals To Present Positive Results From …
Gloucester Pharmaceuticals announced multiple presentations from clinical and preclinical studies of ISTODAX (romidepsin) at the upcoming 51st American.
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals …
… Boston_CP Boston: Gloucester Pharmaceuticals Presents ISTODAX Data Demonstrating Clinical Benefit in Patients with CTCL Includi http://bit.ly/6CGAIM; Oncology_News Oncology News: Alexion Pharmaceuticals announces positive data from …
Gloucester Pharmaceuticals To Present Positive Results From …
Gloucester Pharmaceuticals announced multiple presentations from clinical and preclinical studies of ISTODAX (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, …
Gloucester Pharmaceuticals To Present Positive Results From …
Gloucester Pharmaceuticals To Present Positive Results From Multiple Studies Of ISTODAX(R) At The ASH Annual Meeting Gloucester Pharmaceuticals announced.
Gloucester Pharmaceuticals to Present Positive Results from …
Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of ISTODAX at the ASH Annual Meeting –Poster presentations on studies in.
Stocks in the news: MetLife, McDermott, Intel, Nvidia — DailyFinance
(CELG) will bgloucester pharmaceuticals inc, gloucester pharmaceuticals fk228, romidepsin, Velcade, CTCL, patients, cutaneous T-cell lymphoma, PTCL, Synergistic, B-cell lymphoma, inhibitors, HDAC, systemic therapy, peripheral T-cell lymphoma, treatment, Cell Lines, Non-Hodgkins Lymphomauy privately held Gloucester Pharmaceuticals for as much $640 million to expand further into cancer medicines, the companies said on Monday. Citigroup (C) — The Kuwait Investment Authority, the Gulf nations sovereign …